- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT00360854
Erlotinib Alone or in Combination With Radiation Therapy in Treating Young Patients With Refractory or Relapsed Malignant Brain Tumors or Newly Diagnosed Brain Stem Glioma
Phase I Studies of TARCEVA™ (ERLOTINIB HYDROCHLORIDE, OSI-774) as Single Agent in Children With Refractory and Relapsed Malignant Brain Tumors and in Combination With Irradiation in Newly Diagnosed Brain Stem Glioma
RATIONALE: Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving erlotinib together with radiation therapy may kill more tumor cells.
PURPOSE: This phase I trial is studying the side effects and best dose of erlotinib when given alone or together with radiation therapy in treating young patients with refractory or relapsed malignant brain tumors or newly diagnosed brain stem glioma.
Aperçu de l'étude
Statut
Les conditions
Description détaillée
OBJECTIVES:
Primary
- Establish the maximum tolerated dose of single-agent erlotinib hydrochloride in pediatric patients with refractory or relapsed malignant brain tumors and in combination with radiotherapy in pediatric patients with newly diagnosed brain stem glioma.
Secondary
- Determine dose-limiting toxicities of these regimens.
- Define the safety profile of these regimens.
- Characterize the pharmacokinetic behavior of erlotinib hydrochloride in these patients.
- Evaluate the efficacy of these regimens.
- Correlate expression and mutations of epidermal growth factor receptor with treatment response.
OUTLINE: This is a multicenter, nonrandomized, open-label, dose-escalation study of erlotinib hydrochloride. Patients are assigned to 1 of 2 treatment groups according to disease.
- Group 1 (refractory or relapsed malignant brain tumors): Patients receive oral erlotinib hydrochloride once daily on days 1-21. Treatment repeats every 21 days in the absence of unacceptable toxicity or disease progression.
Cohorts of 3-6 patients receive escalating doses of erlotinib hydrochloride until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity (DLT).
- Group 2 (newly diagnosed brain stem glioma): Patients receive oral erlotinib hydrochloride once daily on days 1-21. Treatment repeats every 21 days in the absence of unacceptable toxicity or disease progression. Beginning on day 1, patients also undergo radiotherapy 5 days a week for 6 weeks .
Cohorts of 1-2 patients receive escalating doses of erlotinib hydrochloride until the MTD is determined. The MTD is defined as the dose resulting in 25% of patients experiencing DLT at 6 weeks.
Blood is collected for pharmacokinetic assessments and pharmacogenetic genotyping for analysis of enzyme polymorphisms. Tumor tissue may be assessed for epidermal growth factor receptor mutations.
After completion of study treatment, patients are followed every 3 months.
PROJECTED ACCRUAL: A total of 48 patients will be accrued for this study.
Type d'étude
Inscription (Anticipé)
Phase
- La phase 1
Contacts et emplacements
Lieux d'étude
-
-
-
Dublin, Irlande, 12
- Our Lady's Hospital for Sick Children Crumlin
-
-
-
-
England
-
Birmingham, England, Royaume-Uni, B4 6NH
- Birmingham Children's Hospital
-
Bristol, England, Royaume-Uni, BS2 8AE
- Institute of Child Health at University of Bristol
-
Cambridge, England, Royaume-Uni, CB2 2QQ
- Addenbrooke's Hospital at Cambridge University Hospitals NHS Foundation Trust
-
Leeds, England, Royaume-Uni, LS9 7TF
- Leeds Cancer Centre at St. James's University Hospital
-
Leicester, England, Royaume-Uni, LE1 5WW
- Leicester Royal Infirmary
-
Liverpool, England, Royaume-Uni, L12 2AP
- Royal Liverpool Children's Hospital, Alder Hey
-
London, England, Royaume-Uni, WC1N 3JH
- Great Ormond Street Hospital for Children NHS Trust
-
London, England, Royaume-Uni, W1T 3AA
- Middlesex Hospital
-
Manchester, England, Royaume-Uni, M27 4HA
- Central Manchester and Manchester Children's University Hospitals NHS Trust
-
Newcastle-Upon-Tyne, England, Royaume-Uni, NE1 4LP
- Sir James Spence Institute of Child Health
-
Nottingham, England, Royaume-Uni, NG7 2UH
- Queen's Medical Centre
-
Oxford, England, Royaume-Uni, 0X3 9DU
- Oxford Radcliffe Hospital
-
Sheffield, England, Royaume-Uni, S10 2TH
- Children's Hospital - Sheffield
-
Southampton, England, Royaume-Uni, SO16 6YD
- Southampton University Hospital NHS Trust
-
Sutton, England, Royaume-Uni, SM2 5PT
- Royal Marsden NHS Foundation Trust - Surrey
-
-
Northern Ireland
-
Belfast, Northern Ireland, Royaume-Uni, BT12 6BE
- Royal Belfast Hospital for Sick Children
-
-
Scotland
-
Aberdeen, Scotland, Royaume-Uni, AB25 2ZG
- Royal Aberdeen Children's Hospital
-
Edinburgh, Scotland, Royaume-Uni, EH9 1LF
- Royal Hospital for Sick Children
-
Glasgow, Scotland, Royaume-Uni, G3 8SJ
- Royal Hospital for Sick Children
-
-
Wales
-
Cardiff, Wales, Royaume-Uni, CF14 4XW
- Childrens Hospital for Wales
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
DISEASE CHARACTERISTICS:
Diagnosis of 1 of the following:
Histologically or cytologically confirmed malignant brain tumor
- Refractory to first-line therapy or relapsed after conventional therapy
- No effective conventional therapy exists
Histologically confirmed brain stem glioma
- Newly diagnosed disease
- No pilocytic glioma
- Measurable or evaluable disease
PATIENT CHARACTERISTICS:
WHO performance status 0-2 OR Lansky play scale 50-100%
- Patients with motor paresis due to disease are eligible
- Neurological deficits must be stable for ≥ 1 week
- Life expectancy ≥ 8 weeks
- Absolute neutrophil count > 1,500/mm³
- Platelet count ≥ 100,000/mm³
- Hemoglobin ≥ 8 g/dL
- AST/ALT ≤ 2.5 times upper limit of normal (ULN)
- Bilirubin ≤ 1.5 times ULN
- Creatinine < 1.5 times ULN OR creatinine clearance ≥ 70 mL/min
- No other serious, uncontrolled illness
- No active infection
- No organ toxicity ≥ grade 2 except alopecia and neurological symptoms due to disease
Must be able to take oral medication
- Patients with newly diagnosed brain stem glioma with difficulty swallowing may be eligible
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
- No evidence of pulmonary dysfunction or pre-existing lung disease
- No myocardial infarction within the past year
- No severe cardiac pathology
No significant ophthalmologic abnormality including, but not limited to, any of the following:
- Severe dry eye syndrome
- Keratoconjunctivitis sicca
- Sjögren's syndrome
- Severe exposure keratitis
- Any other disorder likely to increase the risk of corneal epithelial lesions
PRIOR CONCURRENT THERAPY:
- More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas)
- More than 6 weeks since prior radiotherapy
- No concurrent warfarin
- No other concurrent anticancer or investigational agents
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Non randomisé
- Masquage: Aucun (étiquette ouverte)
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
|---|
|
Maximum tolerated dose of erlotinib hydrochloride when given alone and in combination with radiotherapy
|
Mesures de résultats secondaires
Mesure des résultats |
|---|
|
Sécurité
|
|
Efficacité
|
|
Toxicités dose-limitantes
|
|
Pharmacokinetic behavior of erlotinib hydrocloride
|
|
Correlation of expression and mutations of epidermal growth factor receptor with treatment response
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Darren Hargrave, MD, Royal Marsden NHS Foundation Trust
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Estimation)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
- gliome du tronc cérébral infantile non traité
- épendymome sous-tentoriel de l'enfant
- épendymome supratentoriel de l'enfant
- tumeur neuroectodermique primitive sus-tentorielle récidivante de l'enfant
- astrocytome cérébelleux infantile récurrent
- astrocytome cérébral infantile récurrent
- épendymome infantile récurrent
- tumeur cérébrale infantile récurrente
- médulloblastome infantile récurrent
- voie visuelle infantile récurrente et gliome hypothalamique
- craniopharyngiome infantile
- tumeur germinale du système nerveux central de l'enfant
- tumeur du plexus choroïde chez l'enfant
- méningiome de grade I de l'enfance
- méningiome de grade II de l'enfant
- méningiome de grade III chez l'enfant
- astrocytome cérébral de bas grade chez l'enfant
- pinéoblastome infantile récurrent
- astrocytome sous-épendymaire à cellules géantes récurrent chez l'enfant
Termes MeSH pertinents supplémentaires
- Maladies du cerveau
- Maladies du système nerveux central
- Maladies du système nerveux
- Tumeurs par type histologique
- Tumeurs
- Tumeurs par site
- Tumeurs, glandulaires et épithéliales
- Tumeurs, neuroépithéliales
- Tumeurs neuroectodermiques
- Tumeurs, cellules germinales et embryonnaires
- Tumeurs, tissu nerveux
- Gliome
- Tumeurs cérébrales
- Tumeurs du système nerveux
- Tumeurs du système nerveux central
- Mécanismes moléculaires de l'action pharmacologique
- Inhibiteurs d'enzymes
- Agents antinéoplasiques
- Inhibiteurs de protéine kinase
- Chlorhydrate d'erlotinib
Autres numéros d'identification d'étude
- CDR0000481539
- CCLG-NAG-2005-09
- ITCC-003
- EU-20617
- CCLG-CPP-05-07
- ROCHE-MO18461
- EUDRACT-2004-005247-10
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .